Mandate

Vinge advises Isofol in connection with its listing on Nasdaq Stockholm

Vinge has advised Isofol Medical AB in connection with its listing on Nasdaq Stockholm, with the first day of trading on 21 October 2021. The prospectus was approved by the Swedish Financial Supervisory Authority on 18 October 2021. Isofol has a market value corresponding to approximately SEK 1.5 billion.

Isofol is a biotech company in late clinical phase which develops arfolitixorin in order to improve standard treatment of 5-FE based chemotherapy, primarily for advanced colorectal cancer, by increasing tumour response and progression free survival.

Vinge’s team primarily consisted of Anders StridJenny Sandlund and Edin Agic (Capital Markets), Victor Ericsson and Emelie Svanberg (Tax), Anna Ståhlklo (Commercial Agreements), Alexander Lindeberg (IP) and Rebecka Hansson (Employment Law).

Related

Vinge advises Aspo on its acquisition of Swed Handling

Vinge advises Aspo, listed on Nasdaq Helsinki, in the transaction whereby Aspo's subsidiary Telko expands its chemicals business in Sweden by acquiring Swed Handling, a leading Swedish chemical distributor, from TeRa Invest. As part of the transaction, Aspo’s subsidiary Leipurin expands its food industry business in Sweden, via the technical food ingredient distributor Kebelco, which is a subsidiary of Swed Handling. The closing of the transaction is subject to customary regulatory approvals.
April 30, 2024

Vinge advises on the sale of Vinnergi Holding AB

Vinge has advised Sobro and other shareholders in connection with the sale of Vinnergi Holding AB to Polaris, a Nordic investment firm. In connection with the transaction, the management and employees are reinvesting a significant portion to further develop the company. The Vinnergi Group conducts operations in technology consulting and software development in Sweden, with a particular focus on telecoms, energy and real estate.
April 30, 2024

Vinge has advised Pareto Securities in connection with a rights issue in Episurf Medical

Vinge has advised Pareto Securities in connection with a partially secured rights issue of units of up to approximately SEK 120 million in Episurf Medical.
April 24, 2024